<DOC>
	<DOCNO>NCT00407498</DOCNO>
	<brief_summary>P276-00 specific Cdk4-D1 Cdk1-B inhibitor . P276-00 exhibit significant tumour reduction animal model less adverse effects.Based result various in-vitro study , P276-00 could potential candidate new mechanism base drug treatment cancer.This Phase I study determine Maximum Tolerated Dose , Dose Limiting Toxicity efficacy P 276-00 patient advance Refractory neoplasm .</brief_summary>
	<brief_title>Open Label Phase I Study P276-00 Patients With Advanced Refractory Neoplasms</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Cyclin-Dependent Kinase Inhibitor Proteins</mesh_term>
	<criteria>1 . Patients must histologically and/ cytologically confirm malignancy metastatic unresectable standard curative palliative measure exist longer effective . 2 . Patients either sex , race ethnic group , &gt; 18 year age 3 . ECOG ( Eastern Cooperative Oncology Group ) performance status &lt; 2 4 . Patients life expectancy least 4 month . 5 . Patients must normal organ marrow function define : absolute neutrophil count ≥ 1,500/mL platelet ≥ 100,000/mL total bilirubin within normal institutional limit AST/ALT ≤ 2.5 X institutional upper limit normal ( ULN ) creatinine within 1.5 time upper normal institutional limit 6 . The effect P27600 develop human foetus unknown . For reason woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry , duration study participation least 4 week withdrawal study . 7 . Concomitant medication diabetes , hypertension , pain relief coexist condition , except cancer , permit patient study medication . There change dosage medication 2 week prior day 1 cycle 1 , exception dosage pain relief medication . Changes dose antiemetic diuretic may make provide interfere probable adverse effect investigational product . 8 . Ability understand willingness sign write informed consent document . 9 . Patients must measurable disease . 1 . Patients chemotherapy radiotherapy within 4 week ( 6 week nitrosoureas mitomycin C ) prior enter study ( date consent ) ; patient recover adverse event ( except grade 1 toxicity ) due agent administer 4 week earlier . 2 . Patients receive investigational agent within 4 week prior date consent patient recover completely side effect earlier investigational agent . 3 . Patients know brain metastasis exclude clinical trial . 4 . History allergic reaction attribute compound similar chemical biologic composition P27600 . 5 . Patients history myocardial infarction uncontrolled cardiac dysfunction previous 6 month . 6 . Patients diarrhoea require antidiarrhoeal therapy . 7 . Patients uncontrolled unstable intercurrent illness . 8 . Women pregnant nursing . P27600 may potential teratogenic abortifacient effect . Since unknown potential risk adverse event nurse infant secondary treatment mother P27600 , breastfeed discontinue mother treated P27600 . 9 . Patients immune deficiency increase risk lethal infection treat marrowsuppressive therapy . Therefore , HIVpositive patient exclude study . 10 . Patients require use concomitant medication prolong QT/QTc interval /or know cause Torsades de Pointes ( TdP )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>P 276-00</keyword>
	<keyword>Advanced Refractory Neoplasm</keyword>
	<keyword>Maximum Tolerated Dose</keyword>
	<keyword>Dose Limiting Toxicity</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>